This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 112/25/3846    most recent CIRCULATIONAHA.105.595397v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatine, M. S. Search for Related Content PubMed PubMed Citation Articles by Sabatine, M. S. Related Collections Acute myocardial infarction Heparin Cardiovascular Pharmacology Related Article

(Circulation. 2005;112:3846-3854.)
© 2005 American Heart Association, Inc.

Coronary Heart Disease

Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial

Marc S. Sabatine, MD, MPH; David A. Morrow, MD, MPH; Gilles Montalescot, MD, PhD; Mikael Dellborg, MD; Jose L. Leiva-Pons, MD; Matyas Keltai, MD; Sabina A. Murphy, MPH; Carolyn H. McCabe, BS; C. Michael Gibson, MD, MS; Christopher P. Cannon, MD; Elliott M. Antman, MD; Eugene Braunwald, MD, for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators

From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass (M.S.S., D.A.M., S.A.M., C.H.M., C.M.G., C.P.C., E.M.A., E.B.); Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France (G.M.); Department of Medicine, Sahlgrenska University Hospital, Goteborg, Sweden (M.D.); Interventional Cardiology, Department Hospital Central San Luis Potosi, Mexico (J.L.L.-P.); and Department of Cardiology, Semmelweis University, Hungarian Institute of Cardiology, Budapest, Hungary (M.K.).

Correspondence to Marc S. Sabatine, MD, MPH, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail msabatine{at}partners.org

Received October 14, 2005; revision received October 25, 2005; accepted November 1, 2005.

Background— Low-molecular-weight heparin (LMWH) offers pharmacological and practical advantages over unfractionated heparin (UFH). Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study.

Methods and Results— We compared angiographic and clinical outcomes in patients treated with LMWH (n=1429) versus UFH (n=1431) in CLARITY-TIMI 28, a randomized trial of clopidogrel versus placebo in STEMI patients aged 18 to 75 years undergoing fibrinolysis. After comprehensive adjustment for baseline characteristics, therapeutic interventions, and a propensity score, treatment with LMWH was associated with a significantly lower rate of a closed infarct-related artery or death or myocardial infarction before angiography (13.5% versus 22.5%, adjusted OR 0.76, P=0.027). Treatment with LMWH was also associated with a significantly lower rate of cardiovascular death or recurrent myocardial infarction through 30 days (6.9% versus 11.5%, adjusted OR 0.68, P=0.030). The lower event rates were observed in patients allocated to clopidogrel and in those who underwent percutaneous coronary intervention. Rates of TIMI major bleeding through 30 days (1.6% versus 2.2%, P=0.27) and intracranial hemorrhage (0.6% versus 0.8%, P=0.37) were similar in the LMWH and UFH groups. Patients who received both clopidogrel and LMWH, in addition to a standard fibrinolytic and aspirin, had a particularly high rate of infarct-related artery patency (90.9%) and particularly low rates of cardiovascular death (3.2%), recurrent myocardial infarction (3.0%), and major bleeding (1.8%).

Conclusions— In patients with STEMI receiving fibrinolytic therapy, use of LMWH with other standard therapies, including clopidogrel and aspirin, is associated with improved angiographic outcomes and lower rates of major adverse cardiovascular events.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2005 112: 3815. [Full Text]

This article has been cited by other articles:

				W. E. Boden, K. Eagle, and C. B. Granger Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929. [Abstract] [Full Text] [PDF]

				M. S. Sabatine, D. A. Morrow, A. Dalby, M. Pfisterer, T. Duris, J. Lopez-Sendon, S. A. Murphy, R. Gao, E. M. Antman, E. Braunwald, et al. Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With ST-Segment Elevation Myocardial Infarction Also Treated With Clopidogrel J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2256 - 2263. [Abstract] [Full Text] [PDF]

				R. B. D'Agostino Jr Propensity Scores in Cardiovascular Research Circulation, May 1, 2007; 115(17): 2340 - 2343. [Full Text] [PDF]

				M. S. Sabatine Clopidogrel in ST-elevation myocardial infarction Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G31 - G34. [Abstract] [Full Text] [PDF]

				A. L. Bailey and S. R. Steinhubl Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data. Can. Med. Assoc. J., May 9, 2006; 174(10): 1431 - 1432. [Full Text] [PDF]

				LMWH Promising After Post-STEMI Fibrinolysis Journal Watch Cardiology, January 12, 2006; 2006(112): 3 - 3. [Full Text]